This list concerns blood type distribution between countries and regions. Blood type (also called a blood group) is a classification of blood, based on the presence and absence of antibodies and inherited antigenic substances on the surface of red blood cells (RBCs). These antigens may be proteins, carbohydrates, glycoproteins, or glycolipids, depending on the blood group system.
This section's factual accuracy is disputed .(April 2012) |
Country/Dependency | Population [1] | O+ | A+ | B+ | AB+ | O− | A− | B− | AB− |
---|---|---|---|---|---|---|---|---|---|
Albania [2] | 3,074,579 | 34.1% | 31.2% | 14.5% | 5.2% | 6.0% | 5.5% | 2.6% | 0.9% |
Algeria [3] | 43,576,691 | 40.0% | 30.0% | 15.0% | 4.25% | 6.6% | 2.3% | 1.1% | 0.75% |
Argentina [4] | 45,479,118 | 50.34% | 31.09% | 8.20% | 2.16% | 4.29% | 2.98% | 0.74% | 0.20% |
Armenia [5] | 3,021,324 | 29.0% | 46.3% | 12.0% | 5.6% | 2.0% | 3.7% | 1.0% | 0.4% |
Australia [6] | 25,466,459 | 38.0% | 32.0% | 12.0% | 4.0% | 7.0% | 6.0% | 2.0% | 1.0% |
Austria [7] | 8,859,449 | 30.0% | 37.0% | 12.0% | 5.0% | 6.0% | 7.0% | 2.0% | 0.45% |
Azerbaijan | 10,205,810 | 29.8% | 30.0% | 21.1% | 9.0% | 3.3% | 3.4% | 2.4% | 1.0% |
Bahrain | 1,505,003 | 48.48% | 15.35% | 22.61% | 3.67% | 3.27% | 1.33% | 1.04% | 0.25% |
Bangladesh [8] | 164,098,818 | 29.21% | 26.3% | 33.12% | 9.59% | 0.53% | 0.48% | 0.6% | 0.17% |
Belarus | 9,441,842 | 32.3% | 30.6% | 15.3% | 6.8% | 5.7% | 5.4% | 2.7% | 1.2% |
Belgium [9] | 11,720,716 | 38.0% | 34.0% | 8.5% | 4.0% | 7.0% | 6.0% | 1.5% | 1.0% |
Bhutan [ citation needed ] | 857,423 | 38.15% | 29.45% | 23.86% | 8.41% | 0.06% | 0.04% | 0.04% | 0.01% |
Bolivia | 11,639,909 | 51.53% | 20.45% | 10.11% | 1.15% | 4.39% | 2.73% | 0.54% | 0.1% |
Bosnia and Herzegovina | 3,835,586 | 31.0% | 36.0% | 12.0% | 6.0% | 5.0% | 7.0% | 2.0% | 1.0% |
Brazil [10] | 211,715,973 | 36.0% | 34.0% | 8.0% | 2.5% | 9.0% | 8.0% | 2.0% | 0.5% |
Bulgaria | 6,966,899 | 28.0% | 37.4% | 12.8% | 6.8% | 5.0% | 6.6% | 2.2% | 1.2% |
Burkina Faso [11] | 21,382,659 | 39.94% | 20.79% | 26.34% | 5.17% | 3.36% | 1.75% | 2.22% | 0.43% |
Cambodia | 16,926,984 | 46.7% | 27.2% | 18.5% | 4.9% | 1.3% | 0.8% | 0.5% | 0.1% |
Cameroon [12] | 27,744,989 | 46.83% | 24.15% | 21.06% | 4.29% | 1.79% | 0.92% | 0.8% | 0.16% |
Canada [13] | 37,694,085 | 39.0% | 36.0% | 7.6% | 2.5% | 7.0% | 6.0% | 1.4% | 0.5% |
Chile [14] | 18,186,770 | 55.01% | 28.08% | 8.02% | 1.81% | 4.19% | 2.14% | 0.61% | 0.14% |
Colombia [15] | 49,084,841 | 61.3% | 21.11% | 7.28% | 1.47% | 5.13% | 2.7% | 0.7% | 0.31% |
Costa Rica [16] | 5,097,988 | 49.7% | 28.5% | 12.4% | 3.0% | 3.4% | 1.9% | 0.9% | 0.2% |
Croatia | 4,227,746 | 29.0% | 36.0% | 15.0% | 5.0% | 5.0% | 6.0% | 3.0% | 1.0% |
Cuba | 11,059,062 | 45.8% | 33.5% | 10.2% | 2.9% | 3.6% | 2.8% | 1.0% | 0.2% |
Cyprus [17] | 1,266,676 | 35.22% | 40.35% | 11.11% | 4.72% | 3.85% | 3.48% | 0.87% | 0.40% |
Czech Republic [18] | 10,702,498 | 27.0% | 36.0% | 15.0% | 7.0% | 5.0% | 6.0% | 3.0% | 1.0% |
Democratic Republic of the Congo | 101,780,263 | 59.5% | 21.3% | 15.2% | 2.4% | 1.0% | 0.3% | 0.2% | 0.1% |
Denmark [19] | 5,869,410 | 35.0% | 37.0% | 8.0% | 4.0% | 6.0% | 7.0% | 2.0% | 1.0% |
Dominican Republic | 10,499,707 | 47.2% | 26.4% | 16.9% | 2.1% | 3.7% | 2.1% | 1.4% | 0.2% |
Ecuador | 16,904,867 | 75.0% | 14.0% | 7.1% | 0.5% | 2.38% | 0.7% | 0.3% | 0.02% |
Egypt [20] | 104,124,440 | 36.44% | 33.94% | 20.96% | 8.65% | n/a | n/a | n/a | n/a |
El Salvador [21] | 6,481,102 | 62.0% | 23.0% | 11.0% | 1.0% | 1.0% | 1.0% | 0.7% | 0.3% |
Estonia [22] | 1,228,624 | 29.5% | 30.8% | 20.7% | 6.3% | 4.3% | 4.5% | 3.0% | 0.9% |
Ethiopia | 108,113,150 | 39.0% | 28.0% | 21.0% | 5.0% | 3.0% | 2.0% | 1.0% | 1.0% |
Fiji | 935,974 | 43.0% | 33.3% | 16.5% | 4.8% | 1.0% | 0.7% | 0.5% | 0.2% |
Finland [23] | 5,571,665 | 28.0% | 35.0% | 16.0% | 7.0% | 5.0% | 6.0% | 2.0% | 1.0% |
France [24] | 67,848,156 | 36.5% | 38.2% | 7.7% | 2.5% | 6.5% | 6.8% | 1.4% | 0.4% |
Gabon [25] | 2,284,912 | 57.55% | 20.52% | 17.19% | 2.54% | 1.35% | 0.48% | 0.41% | 0.06% |
Georgia [26] | 4,933,674 | 34.8% | 32.3% | 11.9% | 6.0% | 6.2% | 5.7% | 2.1% | 0.5% |
Germany [27] | 80,159,662 | 35.0% | 37.0% | 9.0% | 4.0% | 6.0% | 6.0% | 2.0% | 1.0% |
Ghana | 29,340,248 | 53.8% | 17.6% | 18.3% | 2.8% | 4.5% | 1.3% | 1.3% | 0.2% |
Greece | 10,607,051 | 37.8% | 32.2% | 11.0% | 4.0% | 6.6% | 5.7% | 2.0% | 0.7% |
Guinea | 12,527,440 | 46.88% | 21.64% | 22.86% | 4.52% | 2.0% | 0.9% | 1.0% | 0.2% |
Honduras | 9,235,340 | 57.5% | 25.0% | 7.8% | 2.5% | 2.7% | 1.7% | 0.6% | 0.2% |
Hong Kong [28] | 7,249,907 | 42.8% | 25.5% | 25.8% | 5.9% | 0.7% | 0.1% | 0.2% | 0.1% |
Hungary | 9,771,827 | 27.0% | 33.0% | 16.0% | 8.0% | 5.0% | 7.0% | 3.0% | 1.0% |
Iceland [29] | 350,734 | 46.8% | 27.2% | 9.0% | 2.0% | 8.2% | 4.8% | 1.6% | 0.4% |
India [30] | 1,339,330,514 | 32.53% | 21.80% | 32.10% | 7.70% | 2.03% | 1.36% | 2.00% | 0.48% |
Indonesia | 267,026,366 | 36.82% | 25.87% | 28.85% | 7.96% | 0.18% | 0.13% | 0.15% | 0.04% |
Iran | 84,923,314 | 36.5% | 27.0% | 22.2% | 4.0% | 5.0% | 2.0% | 2.5% | 0.8% |
Iraq | 38,872,655 | 32.1% | 25.0% | 25.6% | 7.4% | 3.6% | 2.7% | 2.7% | 0.9% |
Ireland [31] | 5,176,569 | 47.0% | 26.0% | 9.0% | 2.0% | 8.0% | 5.0% | 2.0% | 1.0% |
Israel [32] | 8,675,475 | 32.0% | 34.0% | 17.0% | 7.0% | 3.0% | 4.0% | 2.0% | 1.0% |
Italy | 62,402,659 | 39.0% | 36.0% | 7.5% | 2.5% | 7.0% | 6.0% | 1.5% | 0.5% |
Ivory Coast [33] | 28,088,455 | 47.24% | 20.19% | 21.7% | 3.82% | 3.73% | 1.54% | 1.48% | 0.3% |
Jamaica [34] | 2,808,570 | 51.1% | 20.0% | 20.0% | 1.9% | 3.5% | 2.0% | 1.0% | 0.5% |
Japan [35] | 125,507,472 | 29.9% | 39.8% | 19.9% | 9.9% | 0.15% | 0.2% | 0.1% | 0.05% |
Jordan [36] | 10,909,567 | 33.03% | 32.86% | 16.56% | 6.28% | 4.4% | 3.97% | 2.06% | 0.04% |
Kazakhstan | 19,091,949 | 30.7% | 29.8% | 24.2% | 8.3% | 2.3% | 2.2% | 1.8% | 0.4% |
Kenya | 53,527,936 | 45.6% | 25.2% | 21.28% | 4.2% | 1.8% | 1.0% | 0.9% | 0.02% |
Laos [37] | 7,574,356 | 37.52% | 19.73% | 35.36% | 6.85% | 0.2% | 0.1% | 0.2% | 0.05% |
Latvia | 1,881,232 | 30.6% | 31.0% | 17.0% | 6.0% | 5.4% | 6.0% | 3.0% | 1.0% |
Lebanon | 5,469,612 | 38.4% | 32.3% | 9.5% | 3.2% | 7.7% | 6.5% | 1.7% | 0.7% |
Libya | 6,890,535 | 42.64% | 20.86% | 11.19% | 4.5% | 7.26% | 3.24% | 1.64% | 0.67% |
Liechtenstein | 39,137 | 34.0% | 37.0% | 10.0% | 4.0% | 6.0% | 6.5% | 1.8% | 0.7% |
Lithuania | 2,731,464 | 36.0% | 33.0% | 11.0% | 4.0% | 7.0% | 6.0% | 2.0% | 0.7% |
Luxembourg [38] | 628,381 | 35.0% | 37.0% | 9.0% | 4.0% | 6.0% | 6.0% | 2.0% | 1.0% |
Macao | 614,458 | 41.5% | 26.1% | 25.4% | 6.3% | 0.33% | 0.09% | 0.17% | 0.05% |
Malaysia | 32,652,083 | 34.32% | 30.35% | 27.37% | 7.46% | 0.17% | 0.15% | 0.14% | 0.04% |
Malta | 457,267 | 38.0% | 41.0% | 7.0% | 3.0% | 5.0% | 4.5% | 1.0% | 0.5% |
Mauritania [39] | 4,005,475 | 46.3% | 26.68% | 17.47% | 3.85% | 2.8% | 1.6% | 1.1% | 0.2% |
Mauritius | 1,379,365 | 38.3% | 26.0% | 25.0% | 6.7% | 1.7% | 1.0% | 1.0% | 0.3% |
Mexico [40] | 128,649,565 | 59.09% | 26.23% | 8.53% | 1.73% | 2.73% | 1.21% | 0.40% | 0.08% |
Moldova [41] | 3,364,496 | 28.5% | 31.8% | 17.6% | 7.0% | 5.0% | 6.0% | 3.0% | 1.1% |
Mongolia [42] | 3,198,913 | 36.4% | 29.2% | 8.1% | % | 13.3% | 8.0% | 2.0% | 0.01% |
Morocco | 35,561,654 | 42.3% | 30.8% | 14.0% | 4.0% | 4.5% | 3.1% | 1.5% | 0.4% |
Myanmar | 56,590,071 | 35.7% | 23.8% | 32.7% | 6.95% | 0.3% | 0.2% | 0.3% | 0.05% |
Namibia [43] | 2,678,191 | 50.58% | 20.49% | 20.21% | 1.02% | 4.22% | 1.71% | 1.69% | 0.08% |
Nepal | 30,327,877 | 35.2% | 36.3% | 27.1% | 2.6% | 0.3% | 0.2% | 0.2% | 0.1% |
Netherlands [44] | 17,280,397 | 38.2% | 36.6% | 7.7% | 2.5% | 6.8% | 6.4% | 1.3% | 0.5% |
New Zealand [45] | 4,925,477 | 39.0% | 31.0% | 10.0% | 2.0% | 10.9% | 6.0% | 1.0% | 0.1% |
Nicaragua [46] | 6,243,931 | 62.0% | 20.0% | 11.0% | 4.0% | 1.0% | 1.0% | 0.7% | 0.3% |
Nigeria [47] | 219,463,862 | 50.23% | 21.61% | 19.59% | 3.47% | 2.7% | 1.16% | 1.05% | 0.19% |
North Korea | 25,643,466 | 27.15% | 31.08% | 30.15% | 11.32% | 0.08% | 0.1% | 0.1% | 0.03% |
North Macedonia | 2,125,971 | 30.0% | 34.0% | 15.0% | 6.0% | 5.0% | 6.0% | 3.0% | 1.0% |
Norway [48] | 5,467,439 | 33.2% | 41.6% | 6.8% | 3.4% | 5.8% | 7.4% | 1.2% | 0.6% |
Pakistan [ citation needed ] | 238,181,034 | 30.04% | 21.53% | 30.24% | 8.83% | 3.1% | 2.22% | 3.13% | 0.91% |
Papua New Guinea | 7,259,456 | 55.7% | 32.2% | 9.6% | 2.1% | 1.8% | 0.5% | 0.2% | 0.1% |
Paraguay [49] | 7,272,639 | 63.07% | 21.32% | 4.72% | 1.38% | 5.89% | 2.97% | 0.49% | 0.15% |
Peru [50] | 31,914,989 | 70.0% | 18.4% | 7.8% | 1.6% | 1.4% | 0.5% | 0.28% | 0.02% |
Philippines [51] | 109,180,815 | 45.9% | 22.9% | 24.9% | 5.97% | 0.1% | 0.1% | 0.1% | 0.03% |
Poland [52] | 38,282,325 | 31.0% | 32.0% | 15.0% | 7.0% | 6.0% | 6.0% | 2.0% | 1.0% |
Portugal [53] | 10,302,674 | 36.2% | 39.8% | 6.6% | 2.9% | 6.1% | 6.8% | 1.1% | 0.5% |
People's Republic of China [54] | 1,397,897,720 | 34.0% | 27.6% | 28.9% | 8.4% | 0.4% | 0.25% | 0.2% | 0.15% |
Romania [55] | 21,230,362 | 28.0% | 37.0% | 14.0% | 7.0% | 5.0% | 6.0% | 2.0% | 1.0% |
Russia [56] | 145,478,097 | 36.0% | 31.0% | 19.0% | 2.1% | 6.0% | 4.0% | 1.0% | 0.9% |
Saudi Arabia [57] | 34,173,498 | 47.8% | 16.0% | 17.9% | 4.0% | 4.0% | 2.0% | 1.0% | 0.3% |
Serbia | 7,012,165 | 31.92% | 35.28% | 12.6% | 4.2% | 6.08% | 6.72% | 2.4% | 0.8% |
Singapore [58] | 6,209,660 | 44.7% | 23.9% | 24.5% | 5.6% | 0.6% | 0.3% | 0.3% | 0.1% |
Slovakia [59] | 5,440,602 | 27.2% | 35.7% | 15.3% | 6.8% | 4.8% | 6.3% | 2.7% | 1.2% |
Slovenia | 2,102,678 | 31.0% | 33.0% | 12.0% | 6.0% | 7.0% | 7.0% | 3.0% | 1.0% |
Somalia [60] | 12,094,640 | 52.8% | 19.36% | 12.32% | 3.52% | 7.2% | 2.64% | 1.68% | 0.48% |
South Africa [61] | 56,463,617 | 39.0% | 32.0% | 12.0% | 3.0% | 6.0% | 5.0% | 2.0% | 1.0% |
South Korea [62] | 51,835,110 | 29% | 32% | 31% | 8% | 0.19% | 0.1% | 0.1% | 0.01% |
Sri Lanka [63] | 23,044,123 | 43.42% | 21.0% | 25.78% | 5.13% | 2.12% | 1.04% | 1.25% | 0.26% |
Spain [64] | 50,015,792 | 35.0% | 36.0% | 8.0% | 2.5% | 9.0% | 7.0% | 2.0% | 0.5% |
Sudan | 45,561,556 | 48.0% | 27.7% | 15.2% | 2.3% | 3.5% | 1.8% | 0.8% | 0.2% |
Sweden [65] | 10,202,491 | 32.0% | 37.0% | 10.0% | 5.0% | 6.0% | 7.0% | 2.0% | 1.0% |
Switzerland [66] | 8,403,994 | 35.0% | 38.0% | 8.0% | 4.0% | 6.9% | 7.0% | 1.0% | 0.1% |
Syria | 19,398,448 | 43.0% | 30.0% | 14.0% | 3.7% | 5.0% | 3.0% | 1.0% | 0.3% |
Taiwan | 23,603,049 | 43.9% | 25.9% | 23.9% | 6.0% | 0.28% | 0.01% | 0.01% | 0.01% |
Thailand | 68,977,400 | 40.8% | 16.9% | 36.8% | 4.97% | 0.2% | 0.1% | 0.2% | 0.03% |
Tunisia [67] | 11,811,335 | 41.86% | 28.21% | 16.38% | 4.55% | 4.14% | 2.79% | 1.62% | 0.45% |
Turkey [68] | 82,017,514 | 29.4% | 38.3% | 13.2% | 6.4% | 4.4% | 5.5% | 2.1% | 0.7% |
Uganda [69] | 44,712,143 | 49.29% | 24.11% | 20.29% | 4.41% | 1.01% | 0.49% | 0.41% | 0.09% |
Ukraine | 43,922,939 | 32.0% | 34.0% | 15.0% | 5.0% | 5.0% | 6.0% | 2.0% | 1.0% |
United Arab Emirates | 9,992,083 | 44.1% | 21.9% | 20.9% | 4.3% | 4.3% | 2.1% | 2.0% | 0.4% |
United Kingdom [70] | 66,971,395 | 35% | 30% | 8% | 2% | 13% | 5% | 2% | 1% |
United States [71] | 334,998,398 | 37.4% | 35.7% | 8.5% | 3.4% | 9.8% | 4.1% | 1.5% | 0.6% |
Uzbekistan [72] | 30,842,796 | 29.42% | 30.93% | 24.98% | 9.27% | 1.68% | 1.77% | 1.42% | 0.53% |
Venezuela [73] | 28,644,603 | 58.3% | 28.2% | 5.6% | 1.9% | 4.0% | 1.5% | 0.4% | 0.1% |
Vietnam | 98,721,275 | 41.7% | 20.9% | 30.8% | 4.98% | 0.3% | 0.1% | 0.2% | 0.02% |
Yemen | 29,884,405 | 47.84% | 27.5% | 15.32% | 2.14% | 3.66% | 2.1% | 1.17% | 0.16% |
Zimbabwe | 14,546,314 | 36.4% | 29.3% | 8.1% | 2.0% | 14.1% | 8.1% | 2.0% | 0.01% |
World [74] | 7,772,850,805 | 38.4% | 27.3% | 8.1% | 2.0% | 14.1% | 8.1% | 2.0% | 0.01% |
50.0% and above 40.0–49.9% 30.0–39.9% 20.0–29.9% 10.0–19.9% 5.0–9.9%
Ethnic distribution of ABO (without Rh) blood types [75] (This table has more entries than the table above but does not distinguish between Rh types.) | ||||
---|---|---|---|---|
People group | O (%) | A (%) | B (%) | AB (%) |
Australian Aboriginals | 61 | 39 | 0 | 0 |
Abyssinians | 43 | 27 | 25 | 5 |
Ainu (Japan) | 17 | 32 | 32 | 18 |
Albanians | 38 | 43 | 13 | 6 |
Great Andamanese | 9 | 60 | 20 | 12 |
Arabs | 34 | 31 | 29 | 6 |
Armenians | 31 | 50 | 13 | 6 |
Asian Americans | 40 | 28 | 27 | 5 |
Austrians | 36 | 44 | 13 | 6 |
Bantus | 46 | 30 | 19 | 5 |
Basques | 51 | 44 | 4 | 1 |
Belgians | 47 | 42 | 8 | 3 |
Bororo (Brazil) | 100 | 0 | 0 | 0 |
Brazilians | 47 | 41 | 9 | 3 |
Bulgarians | 32 | 44 | 15 | 8 |
Bamar people | 36 | 24 | 33 | 7 |
Buryats (Siberia) | 33 | 21 | 38 | 8 |
Bushmen | 56 | 34 | 9 | 2 |
Chinese-Canton | 47 | 23 | 25 | 4 |
Chinese-Ningbo | 35 | 32 | 25 | 9 |
Chinese-Yangzhou | 31 | 32 | 27 | 7 |
Chinese-Peking | 29 | 27 | 32 | 13 |
Chuvash | 30 | 29 | 33 | 7 |
Croats | 34 | 42 | 17 | 7 |
Czechs | 30 | 44 | 18 | 9 |
Danes | 41 | 44 | 11 | 4 |
Dutch | 45 | 43 | 9 | 3 |
Egyptians | 33 | 36 | 24 | 8 |
English | 47 | 41 | 9 | 3 |
Inuit (Alaska) | 38 | 44 | 13 | 5 |
Inuit (Greenland) | 57 | 36 | 23 | 5 |
Estonians | 34 | 36 | 23 | 8 |
Fijians | 44 | 34 | 17 | 6 |
Finns | 34 | 41 | 18 | 7 |
French | 43 | 47 | 7 | 3 |
Georgians | 46 | 37 | 12 | 4 |
Germans | 41 | 43 | 11 | 5 |
Greeks | 44 | 38 | 14 | 5 |
Romani people (Hungary) | 29 | 27 | 35 | 10 |
Hawaiians | 37 | 61 | 2 | 1 |
Hindus (Bombay) | 32 | 29 | 28 | 11 |
Hungarians | 36 | 43 | 19 | 8 |
Icelanders | 56 | 32 | 10 | 3 |
Indians (India) | 37 | 22 | 33 | 7 |
Native Americans (US) | 79 | 16 | 4 | 1 |
Irish | 52 | 35 | 10 | 1 |
Italians (Milan) | 46 | 41 | 11 | 3 |
Japanese | 30 | 38 | 22 | 10 |
Jews (Germany) | 42 | 41 | 12 | 5 |
Jews (Poland) | 33 | 41 | 18 | 8 |
Kalmyks | 26 | 23 | 41 | 11 |
Kikuyu (Kenya) | 60 | 19 | 20 | 1 |
Koreans | 28 | 32 | 31 | 9 |
Sami people | 29 | 63 | 4 | 4 |
Latvians | 32 | 37 | 24 | 7 |
Lithuanians | 40 | 34 | 20 | 6 |
Malays | 62 | 18 | 20 | 0 |
Māori | 46 | 54 | 1 | 0 |
Mayans | 98 | 1 | 1 | 1 |
Moros | 64 | 16 | 20 | 0 |
Navajo Indians | 73 | 27 | 0 | 0 |
Nicobarese | 74 | 9 | 15 | 1 |
Norwegians | 39 | 50 | 8 | 4 |
Papuans (New Guinea) | 41 | 27 | 23 | 9 |
Persians | 38 | 33 | 22 | 7 |
Peruvian Indians | 100 | 0 | 0 | 0 |
Filipinos | 45 | 22 | 27 | 6 |
Poles | 33 | 39 | 20 | 9 |
Portuguese | 35 | 53 | 8 | 4 |
Romanians | 33 | 43 | 16 | 8 |
Russians | 33 | 36 | 23 | 8 |
Sardinians | 50 | 26 | 19 | 5 |
Scots | 51 | 34 | 12 | 3 |
Serbs | 38 | 42 | 16 | 5 |
Shompen Nicobarese | 100 | 0 | 0 | 0 |
Slovaks | 37 | 42 | 16 | 5 |
South Africans | 45 | 40 | 11 | 4 |
Spanish | 38 | 47 | 10 | 5 |
Sudanese | 62 | 16 | 21 | 0 |
Swedish | 36 | 45 | 12 | 7 |
Swiss | 38 | 50 | 9 | 3 |
Tatars | 28 | 30 | 29 | 13 |
Thais | 32 | 21 | 36 | 9 |
Turks | 43 | 33 | 19 | 6 |
Ukrainians | 37 | 40 | 18 | 6 |
African Americans | 49 | 27 | 20 | 4 |
White Americans | 45 | 40 | 11 | 4 |
Vietnamese | 42 | 22 | 30 | 5 |
Blood group B has its highest frequency in the Middle East, where it ranks as the largest share of the population. In Southeast Asia its share of the population is lowest, especially in Indonesia, secondarily in East Asia, Northern Asia and neighboring Central Asia, and its incidence diminishes both towards the east and the west, falling to single-digit percentages in Netherlands, Norway, Portugal and Switzerland. [76] [77] It is believed to have been entirely absent from Native American and Australian Aboriginal populations prior to the arrival of Europeans in those areas. [77] [78]
Blood group A is associated with high frequencies in Europe, especially in Scandinavia and Central Europe, although its highest frequencies occur in some Australian Aboriginal populations and the Blackfoot Indians of Montana, US. [79] [80]
In the ABO blood group system, there are three alleles: i, IA, and IB. As both IA and IB are dominant over i, only ii people have type O blood. Individuals with IAIA or IAi have type A blood, and individuals with IBIB or IBi have type B. Those with IAIB have type AB.
A blood type is a classification of blood, based on the presence and absence of antibodies and inherited antigenic substances on the surface of red blood cells (RBCs). These antigens may be proteins, carbohydrates, glycoproteins, or glycolipids, depending on the blood group system. Some of these antigens are also present on the surface of other types of cells of various tissues. Several of these red blood cell surface antigens can stem from one allele and collectively form a blood group system.
Rh disease is a type of hemolytic disease of the fetus and newborn (HDFN). HDFN due to anti-D antibodies is the proper and currently used name for this disease as the Rh blood group system actually has more than 50 antigens and not only the D-antigen. The term "Rh Disease" is commonly used to refer to HDFN due to anti-D antibodies, and prior to the discovery of anti-Rho(D) immune globulin, it was the most common type of HDFN. The disease ranges from mild to severe, and occurs in the second or subsequent pregnancies of Rh-D negative women when the biologic father is Rh-D positive.
Hemolytic disease of the newborn, also known as hemolytic disease of the fetus and newborn, HDN, HDFN, or erythroblastosis fetalis, is an alloimmune condition that develops in a fetus at or around birth, when the IgG molecules produced by the mother pass through the placenta. Among these antibodies are some which attack antigens on the red blood cells in the fetal circulation, breaking down and destroying the cells. The fetus can develop reticulocytosis and anemia. The intensity of this fetal disease ranges from mild to very severe, and fetal death from heart failure can occur. When the disease is moderate or severe, many erythroblasts are present in the fetal blood, earning these forms of the disease the name erythroblastosis fetalis.
The ABO blood group system is used to denote the presence of one, both, or neither of the A and B antigens on erythrocytes. For human blood transfusions, it is the most important of the 44 different blood type classification systems currently recognized by the International Society of Blood Transfusions (ISBT) as of December 2022. A mismatch in this serotype can cause a potentially fatal adverse reaction after a transfusion, or an unwanted immune response to an organ transplant. Such mismatches are rare in modern medicine. The associated anti-A and anti-B antibodies are usually IgM antibodies, produced in the first years of life by sensitization to environmental substances such as food, bacteria, and viruses.
Cross-matching or crossmatching is a test performed before a blood transfusion as part of blood compatibility testing. Normally, this involves adding the recipient's blood plasma to a sample of the donor's red blood cells. If the blood is incompatible, the antibodies in the recipient's plasma will bind to antigens on the donor red blood cells. This antibody-antigen reaction can be detected through visible clumping or destruction of the red blood cells, or by reaction with anti-human globulin. Along with blood typing of the donor and recipient and screening for unexpected blood group antibodies, cross-matching is one of a series of steps in pre-transfusion testing. In some circumstances, an electronic cross-match can be performed by comparing records of the recipient's ABO and Rh blood type against that of the donor sample. In emergencies, blood may be issued before cross-matching is complete. Cross-matching is also used to determine compatibility between a donor and recipient in solid organ transplantation including heart/lung transplation.
In ABO hemolytic disease of the newborn maternal IgG antibodies with specificity for the ABO blood group system pass through the placenta to the fetal circulation where they can cause hemolysis of fetal red blood cells which can lead to fetal anemia and HDN. In contrast to Rh disease, about half of the cases of ABO HDN occur in a firstborn baby and ABO HDN does not become more severe after further pregnancies.
Hemolytic disease of the newborn (anti-Kell1) is the second most common cause of severe hemolytic disease of the newborn (HDN) after Rh disease. Anti-Kell1 is becoming relatively more important as prevention of Rh disease is also becoming more effective.
Hemolytic disease of the newborn (anti-Rhc) can range from a mild to a severe disease. It is the third most common cause of severe HDN. Rh disease is the most common and hemolytic disease of the newborn (anti-Kell) is the second most common cause of severe HDN. It occurs more commonly in women who are Rh D negative.
The term human blood group systems is defined by the International Society of Blood Transfusion (ISBT) as systems in the human species where cell-surface antigens—in particular, those on blood cells—are "controlled at a single gene locus or by two or more very closely linked homologous genes with little or no observable recombination between them", and include the common ABO and Rh (Rhesus) antigen systems, as well as many others; 44 human systems are identified as of 31 December 2022.
The Kell antigen system is a human blood group system, that is, a group of antigens on the human red blood cell surface which are important determinants of blood type and are targets for autoimmune or alloimmune diseases which destroy red blood cells. The Kell antigens are K, k, Kpa, Kpb, Jsa and Jsb. The Kell antigens are peptides found within the Kell protein, a 93-kilodalton transmembrane zinc-dependent endopeptidase which is responsible for cleaving endothelin-3.
The Rh blood group system is a human blood group system. It contains proteins on the surface of red blood cells. After the ABO blood group system, it is the most likely to be involved in transfusion reactions. The Rh blood group system consisted of 49 defined blood group antigens in 2005. As of 2023, there are over 50 antigens among which the five antigens D, C, c, E, and e are among the most prominent. There is no d antigen. Rh(D) status of an individual is normally described with a positive (+) or negative (−) suffix after the ABO type. The terms Rh factor, Rh positive, and Rh negative refer to the Rh(D) antigen only. Antibodies to Rh antigens can be involved in hemolytic transfusion reactions and antibodies to the Rh(D) and Rh antigens confer significant risk of hemolytic disease of the newborn.
Animal erythrocytes have cell surface antigens that undergo polymorphism and give rise to blood types. Antigens from the human ABO blood group system are also found in apes and Old World monkeys, and the types trace back to the origin of humanoids. Other animal blood sometimes agglutinates with human blood group reagents, but the structure of the blood group antigens in animals is not always identical to those typically found in humans. The classification of most animal blood groups therefore uses different blood typing systems to those used for classification of human blood.
Packed red blood cells, also known as packed cells, are red blood cells that have been separated for blood transfusion. The packed cells are typically used in anemia that is either causing symptoms or when the hemoglobin is less than usually 70–80 g/L. In adults, one unit brings up hemoglobin levels by about 10 g/L. Repeated transfusions may be required in people receiving cancer chemotherapy or who have hemoglobin disorders. Cross-matching is typically required before the blood is given. It is given by injection into a vein.
Hemolytic disease of the newborn (anti-RhE) is caused by the anti-RhE antibody of the Rh blood group system. The anti-RhE antibody can be naturally occurring, or arise following immune sensitization after a blood transfusion or pregnancy.
Rh-associated glycoprotein (RHAG) is an ammonia transporter protein that in humans is encoded by the RHAG gene. RHAG has also recently been designated CD241. Mutations in the RHAG gene can cause stomatocytosis.
This page is currently under construction.
Rh blood group, D antigen also known as Rh polypeptide 1 (RhPI) or cluster of differentiation 240D (CD240D) is a protein that in humans is encoded by the RHD gene.
Blood compatibility testing is conducted in a medical laboratory to identify potential incompatibilities between blood group systems in blood transfusion. It is also used to diagnose and prevent some complications of pregnancy that can occur when the baby has a different blood group from the mother. Blood compatibility testing includes blood typing, which detects the antigens on red blood cells that determine a person's blood type; testing for unexpected antibodies against blood group antigens ; and, in the case of blood transfusions, mixing the recipient's plasma with the donor's red blood cells to detect incompatibilities (crossmatching). Routine blood typing involves determining the ABO and RhD type, and involves both identification of ABO antigens on red blood cells and identification of ABO antibodies in the plasma. Other blood group antigens may be tested for in specific clinical situations.
The Lan blood group system is a human blood group defined by the presence or absence of the Lan antigen on a person's red blood cells. More than 99.9% of people are positive for the Lan antigen. Individuals with the rare Lan-negative blood type, which is a recessive trait, can produce an anti-Lan antibody when exposed to Lan-positive blood. Anti-Lan antibodies may cause transfusion reactions on subsequent exposures to Lan-positive blood, and have also been implicated in mild cases of hemolytic disease of the newborn. However, the clinical significance of the antibody is variable. The antigen was first described in 1961, and Lan was officially designated a blood group in 2012.
The monocyte monolayer assay (MMA) is used to determine the clinical significance of alloantibodies produced by blood transfusion recipients. The assay is used to assess the potential for intravascular hemolysis when incompatible cellular blood products are transfused to the anemic patient. When donor cells possess substances that are not produced by the recipient, the recipient's immune system produces antibodies against the substance; these are called alloantibodies. Specific white blood cells, called monocytes, are tasked with ingesting foreign material and become activated during certain inflammatory events. These activated monocytes come in contact with antibody-sensitized red blood cells (RBC) and may or may not exhibit phagocytosis (ingestion) and destroy the donor red blood cells. If monocytes destroy the RBC, the antibody attached to those RBC is considered clinically significant.
{{citation}}
: Missing or empty |title=
(help)... In northern India, in Southern and Central China and in the neighboring Central Asiatic areas, we find the highest known frequencies of B. If we leave this center, the frequency of the B gene decreases almost everywhere ...
... The maximum frequency of the B gene occurs in Central Asia and northern India. The B gene was probably absent from Native Americans and Australian Aboriginal people before racial admixture occurred with the coming of the white man ...
... Blood type B is completely absent in most North and South American Indians ...
Blood Type A: Central and Eastern Europe. Type A is common in Central and Eastern Europe. In countries such as Austria, Denmark, Norway, and Switzerland, about 45–50% of the population have this blood type, whereas about 40% of Poles and Ukrainians do so. The highest frequencies are found in small, unrelated populations. For example, about 80% of the Blackfoot Indians of Montana have blood type A ...
... The frequency of blood group A is quite high (25–55%) in Europe, especially in Scandinavia and parts of central Europe. High group A frequency is also found in the Aboriginal people of South Australia (up to 45%) and in certain American Indian tribes where the frequency reaches 35% ...